Rate My Professor Stephen Ackland

Ackland's research focuses on the basic and clinical pharmacology of anticancer drugs, including measurement, pharmacokinetics, pharmacodynamics, and genetics/genomics, alongside clinical trials in medical oncology. He has produced over 150 peer-reviewed publications, with 31 as first author, and co-owns two patents. Key publications include 'Thymidylate synthase inhibitors' (2003), 'Antifolates in Combination Therapy' (1999), 'A phase I dose-escalation study of an all-in-one 5-fluorouracil and leucovorin co-formulation administered after failure of standard treatment' (2024, Journal of Clinical Oncology), 'SPAR: A randomized placebo-controlled phase 2 trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer' (2022, Journal of Clinical Oncology), and 'DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine' (2022, Annals of Oncology). His impact is evident in extensive leadership: Director of Hunter Cancer Research Alliance (2011-2019), Chair of HMRI Cancer Research Program (2003-2019), Director of University of Newcastle Priority Research Centre for Cancer Research Innovation and Translation, Co-director of Hunter Medical Research Institute Cancer Research Program, Area Director of Clinical Cancer Research Network HNE Health, Editor-in-Chief of Asia-Pacific Journal of Clinical Oncology (2005-present), President of Clinical Oncological Society of Australia (2004-2005), Chairman of Medical Oncology Group of Australia (1999-2000), and board member of Cancer Council NSW (2006-2014) and ANZ Breast Cancer Trials Group (2007-2017, Chairman 2015-2017). Awards encompass the MOGA Cancer Achievement Award (2019) and Medical Oncology Group/GSK Travel Award (2001).